Advanced search
Publication Cover
OncoTargets and Therapy Volume 10, 2017 - Issue
Submit an article Journal homepage
115
Views
13
CrossRef citations to date
0
Altmetric
Original Research

Skin toxicity evaluation in patients treated with cetuximab for metastatic colorectal cancer: a new tool for more accurate comprehension of quality of life impacts

Michele De Tursi1 Department of Medical, Oral and Biotechnological Sciences, Medical Oncology UnitCorrespondence[email protected]
,
Marinella Zilli1 Department of Medical, Oral and Biotechnological Sciences, Medical Oncology Unit
,
Consiglia Carella1 Department of Medical, Oral and Biotechnological Sciences, Medical Oncology Unit
,
Matteo Auriemma2 Department of Dermatology and Venereology
,
Maria Nadia Lisco2 Department of Dermatology and Venereology
,
Marta Di Nicola3 Laboratory of Biostatistics, Department of Medical, Oral and Biotechnological Sciences
,
Giuseppe Di Martino4 Department of Medicine and Aging Science, University degli Studi “G d’Annunzio” Chieti-Pescara, Chieti, Italy
,
Clara Natoli1 Department of Medical, Oral and Biotechnological Sciences, Medical Oncology Unit
&
Paolo Amerio2 Department of Dermatology and Venereology
 show all
Pages 3007-3015 | Published online: 16 Jun 2017

References

  • CiardielloFTortoraGA novel approach in the treatment of cancer: targeting the epidermal growth factor receptorClin Cancer Res20017102958297011595683
  • CitriAYardenYEGF-ERBB signalling: towards the systems levelNat Rev Mol Cell Biol20067750551616829981
  • MasciaFCataissonCLeeTCEGFR regulates the expression of keratinocyte-derived granulocyte/macrophage colony-stimulating factor in vitro and in vivoJ Invest Dermatol2010130368269319890352
  • RegoRLFosterNRSmyrkTCPrognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR statusBr J Cancer2010102116517219997103
  • AmadoRGWolfMPeetersMWild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancerJ Clin Oncol200826101626163418316791
  • KarapetisCSKhambata-FordSJonkerDJK-ras mutations and benefit from cetuximab in advanced colorectal cancerN Engl J Med2008359171757176518946061
  • Van CutsemEKöhneCHLángICetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation statusJ Clin Oncol201129152011201921502544
  • DouillardJYSienaSCassidyJRandomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME studyJ Clin Oncol201028314697470520921465
  • BokemeyerCBondarenkoIMakhsonAFluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancerJ Clin Oncol200927566367119114683
  • MitchellEPPerez-SolerRVan CutsemELacoutureMEClinical presentation and pathophysiology of EGFRI dermatologic toxicitiesOncology (Williston Park)20072111 Suppl 54918154212
  • UrbanCAnadkatMJA review of cutaneous toxicities from targeted therapies in the treatment of colorectal cancersJ Gastrointest Oncol20134331932723997943
  • AgeroALDuszaSWBenvenuto-AndradeCBusamKJMyskowskiPHalpernACDermatologic side effects associated with the epidermal growth factor receptor inhibitorsJ Am Acad Dermatol200655465767017010747
  • JoshiSSOrtizSWitherspoonJNEffects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of lifeCancer2010116163916392320564072
  • Abdel-RahmanOFouadMCorrelation of cetuximab-induced skin rash and outcomes of solid tumor patients treated with cetuximab: a systematic review and meta-analysisCrit Rev Oncol Hematol201593212713525139841
  • PintoCBaroneCAGirolomoniGManagement of skin reactions during Cetuximab treatment in association with chemotherapy or radiotherapyAm J Clin Oncol201639440741527077276
  • NCI-CTCAE v.4 Available from: http://evs.nci.nih.gov/ftp1/CTCAE/About.htmlAccessed November 16, 2016
  • BaschEIasonosAMcDonoughTPatient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based studyLancet Oncol200671190390917081915
  • WagnerLIBergSRGandhiMThe development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18)Support Care Cancer20132141033104123128934
  • LacoutureMEMaitlandMLSegaertSA proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study groupSupport Care Cancer201018450952220145956
  • ChanATanEHHow well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors?Support Care Cancer201119101667167420820812
  • LacoutureMEAnadkatMJBensadounRJClinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicitiesSupport Care Cancer20111981079109521630130
  • ChrenMMLasekRJFlockeSAZyzanskiSJImproved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseasesArch Dermatol199713311143314409371029
  • NijstenTESampognaFChrenMMAbeniDDTesting and reducing skindex-29 using Rasch analysis: Skindex-17J Invest Dermatol200612661244125016543899
  • DorosGLewRDesign based on intra-class correlation coefficientsAm J Biostat2010118

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.